Related Experiment Video

Updated: Dec 21, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

MicroRNA-365 inhibits the progression of lung adenocarcinoma through targeting ETS1 and inactivating AKT/mTOR pathway

L Tong1, W-Z Han, J-L Wang

  • 1Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, P.R. China. lj198132@163.com.

European Review for Medical and Pharmacological Sciences
|May 21, 2020
PubMed
Abstract

Insights

MicroRNA-365 (miR-365) inhibits lung adenocarcinoma progression by targeting ETS1 and the AKT/mTOR pathway. This finding offers new insights into lung cancer regulation and potential therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • MicroRNAs (miRNAs) are key regulators of gene expression implicated in human cancers.
  • Dysregulation of miR-365 is observed in various cancers, but its role in lung adenocarcinoma is unclear.
  • Understanding miR-365's mechanism is crucial for developing targeted lung cancer therapies.

Purpose of the Study:

  • To investigate the regulatory mechanism of miR-365 in lung adenocarcinoma.
  • To determine the functional role of miR-365 in lung adenocarcinoma cell behavior.
  • To elucidate the molecular pathways targeted by miR-365.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to assess miR-365 and ETS1 expression in cell lines and patient tissues.
  • Kaplan-Meier analysis to correlate miR-365 expression with patient survival.
  • Transwell assays to evaluate the impact of miR-365 on cell migration and invasion.

Main Results:

  • miR-365 was downregulated, while ETS1 was upregulated in lung adenocarcinoma.
  • Overexpression of miR-365 suppressed proliferation, migration, and invasion of lung adenocarcinoma cells.
  • miR-365 inhibited epithelial-mesenchymal transition (EMT) and inactivated the AKT/mTOR pathway, with ETS1 upregulation counteracting these effects.

Conclusions:

  • miR-365 acts as a tumor suppressor in lung adenocarcinoma.
  • The inhibitory effect of miR-365 on lung adenocarcinoma progression is mediated through targeting ETS1 and inactivating the AKT/mTOR pathway.
  • miR-365 represents a potential therapeutic target for lung adenocarcinoma.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.9K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K